In treatment of giardiasis, nitazoxanide was superior to placebo and comparable to Nitazoxanide is also under investigation for the treatment of Nitazoxanide showed moderate to high inhibitory efficacy against COVID-19 PL protease as demonstrated by in silico study.Nitazoxanide is currently available in two oral dosage forms: a tablet (500 mg) and an oral Nitazoxanide is sold under the brand names Adonid, Alinia, Allpar, Annita, Celectan, Colufase, Daxon, Dexidex, Diatazox, Kidonax, Mitafar, Nanazoxid, Parazoxanide, Netazox, Niazid, Nitamax, Nitax, Nitaxide, Nitaz, Nizonide, "Alinia" redirects here. For the insect genus, see InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)[2-[(5-Nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate Please update this article to reflect recent events or newly available information.World Journal of Gastroenterology 2009 April 21, Emmet B Keeffe MD, Professor, Jean-François Rossignol The Romark Institute for Medical Research, Tampa Nitazoxanide is used to treat diarrhea caused by Giardia or Cryptosporidium. Enteric protozoal infections such as giardiasis, amebiasis and cryptosporidiosis are among the most common and most prevalent forms of gastrointestinal parasitic infections worldwide. The MIC values for nitazoxanide in the H. pylori isolates resistant to metronidazole are presented in Table 2. Protozoa are suspected as the cause when diarrhea lasts more than 7 days. Nitazoxanide is an antiparasitic agent with specific indications for treatment of cryptosporidiosis and giardiasis in children. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. They found small differences in favor of nitazoxanide in comparison with probiotics and concluded that nitazoxanide is an important treatment option for rotavirus diarrhea.A retrospective review of charts of patients treated with nitazoxanide for trichomoniasis by Michael Dan and Jack D. Sobel demonstrated a negative result. Diarrhea is caused by a blend of bacterial, viral and parasitic pathogens. It is indicated for the treatment of infection by Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals and has been repurposed for the treatment of influenza. They reported three case studies; two of which with metronidazole-resistant infections. In two double-blind, controlled trials in pediatric patients with diarrhea and with or without enteric symptoms (e.g., abdominal distention, colic, left iliac fossa tenderness) caused by Cryptosporidium parvum, a three-day course of treatment with nitazoxanide (100 mg BID in pediatric patients ages 12-47 months, 200 mg BID in pediatric patients ages 4 through 11 years) was compared with a placebo.

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral drug that is used in medicine for the treatment of various helminthic, protozoal, and viral infections. 16 Nitazoxanide is a nitrothiazolyl-salicylamide derivative, whose activity appears to be at the level of electron transfer of anaerobic metabolism. Nitazoxanide has also been shown to have in vitro antiparasitic activity and clinical treatment efficacy for infections caused by other prot In Zambia and in a study conducted in Mexico, nitazoxanide was not successful in the treatment of cryptosporidiosis in advanced infection with human immunodeficiency virus at the doses used. However, it was effective in patients with higher CD4 counts. Nitazoxanide is used to treat diarrhea in children and adults caused by the protozoa Cryptosporidium or Giardia. Diarrheal disease is a leading cause of illness and death in children worldwide. A randomised double-blind placebo-controlled study published in 2006, with a group of 38 young children (Lancet, vol 368, page 124-129)Teran et al.. conducted a study at the Pediatric Center Albina Patinö, a reference hospital in the city of Cochabamba, Bolivia, from August 2007 to February 2008. In a double-blind, controlled trial conducted in Egypt in adults and adolescents with diarrhea with or without enteric symptoms (e.g., abdominal pain/cramps, nausea, vomiting) caused by In a second double-blind, placebo-controlled trial of nitazoxanide tablets conducted in Egypt In a double-blind, controlled trial (Study 1) conducted in Peru and Egypt in adults and adolescents with diarrhea with one or more enteric symptoms (e.g., abdominal pain, nausea, vomiting, fever, abdominal distention, loss of appetite, flatulence) caused by In a randomized, controlled trial conducted in Peru in 110 pediatric patients with diarrhea with or without enteric symptoms (e.g., abdominal distension, right iliac fossa tenderness) caused by A double-blind, placebo-controlled trial did not produce clinical cure rates that were significantly different from the placebo control when conducted in hospitalized, severely malnourished pediatric patients with acquired immune deficiency syndrome (AIDS) in Zambia.